A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls.
A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls.
复制标题
DOI：
10.1186/s13075-016-0982-5
复制
发表时间：
2016-04-12
影响因子：
4.9
通讯作者：
Huffman KM
中科院分区：
文献类型：
--
作者：
Bartlett DB;Connelly MA;AbouAssi H;Bateman LA;Tune KN;Huebner JL;Kraus VB;Winegar DA;Otvos JD;Kraus WE;Huffman KM
RA和CVD都有炎症作为基础生物学的一部分。我们的目的是探讨GlycA（一种糖基化急性时相蛋白）与RA炎症和心脏代谢风险的关系，并探讨这些关系是否与非RA患者相似。血浆GlycA测定了50名轻中度RA疾病活动的个体和39名年龄，性别和体重指数（BMI）匹配的对照组。进行回归分析以评估GlycA与传统炎症和心脏代谢健康的重要标志物之间的关系：炎性细胞因子，疾病活动，肥胖和胰岛素抵抗的测量。平均而言，RA活性较低（DAS-28 = 3.0 ± 1.4）。RA患者的传统炎症标志物ESR、hsCRP、IL-1β、IL-6、IL-18和TNF-α均高于对照组（均P < 0.05）。GlycA浓度在RA组显著高于对照组（P = 0.036）。在RA中，GlycA升高与疾病活动相关（DAS-28; RDAS-28 = 0.5）和炎症（RESR = 0.7，RhsCRP = 0.7，RIL-6 = 0.3：P < 0.05）;在BMI匹配的对照组中，这些炎症相关性不存在或较弱（hsCRP），但GlycA与IL-18相关（RhsCRP = 0.3，RIL-18 = 0.4：P < 0.05）。在类风湿关节炎中，GlycA水平越高，腹部肥胖程度越高，肌肉密度越低（Rabdominal-adiposity = 0.3，Rmuscle-density =-0.3，P < 0.05）。在BMI匹配的对照组中，GlycA与更多的心脏代谢标志物相关：BMI，腰围，肥胖测量和胰岛素抵抗（R = 0.3-0.6，P < 0.05）。GlycA提供了一个综合的炎症指标，其贡献来自传统的炎症标志物和心脏代谢来源，主要是RA患者的炎症标志物和非RA患者的心脏代谢因素。
RA and CVD both have inflammation as part of the underlying biology. Our objective was to explore the relationships of GlycA, a measure of glycosylated acute phase proteins, with inflammation and cardiometabolic risk in RA, and explore whether these relationships were similar to those for persons without RA. Plasma GlycA was determined for 50 individuals with mild-moderate RA disease activity and 39 controls matched for age, gender, and body mass index (BMI). Regression analyses were performed to assess relationships between GlycA and important markers of traditional inflammation and cardio-metabolic health: inflammatory cytokines, disease activity, measures of adiposity and insulin resistance. On average, RA activity was low (DAS-28 = 3.0 ± 1.4). Traditional inflammatory markers, ESR, hsCRP, IL-1β, IL-6, IL-18 and TNF-α were greater in RA versus controls (P < 0.05 for all). GlycA concentrations were significantly elevated in RA versus controls (P = 0.036). In RA, greater GlycA associated with disease activity (DAS-28; RDAS-28 = 0.5) and inflammation (RESR = 0.7, RhsCRP = 0.7, RIL-6 = 0.3: P < 0.05 for all); in BMI-matched controls, these inflammatory associations were absent or weaker (hsCRP), but GlycA was related to IL-18 (RhsCRP = 0.3, RIL-18 = 0.4: P < 0.05). In RA, greater GlycA associated with more total abdominal adiposity and less muscle density (Rabdominal-adiposity = 0.3, Rmuscle-density = −0.3, P < 0.05 for both). In BMI-matched controls, GlycA associated with more cardio-metabolic markers: BMI, waist circumference, adiposity measures and insulin resistance (R = 0.3-0.6, P < 0.05 for all). GlycA provides an integrated measure of inflammation with contributions from traditional inflammatory markers and cardio-metabolic sources, dominated by inflammatory markers in persons with RA and cardio-metabolic factors in those without.